Hims & Hers (HIMS) is expanding aggressively in telehealth, positioning itself as a scalable platform for peptides and broader treatments, according to Raul Shah. He highlights its manufacturing advantage, a strategic shift with Novo Nordisk (NVO), and global expansion efforts as the company targets partnerships with major players like Eli Lilly (LLY).